Expression of miRNA‑206 and miRNA‑145 in breast cancer and correlation with prognosis

Quan,Yan; Huang,Xianxi; Quan,Xiaoxiang

doi:10.3892/ol.2018.9440

Expression of miRNA‑206 and miRNA‑145 in breast cancer and correlation with prognosis

Authors:
- Yan Quan
- Xianxi Huang
- Xiaoxiang Quan
View Affiliations

Affiliations: Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China, Department of Molecular Laboratory, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China, Department of General Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515041, P.R. China
Published online on: September 17, 2018 https://doi.org/10.3892/ol.2018.9440
Pages: 6638-6642
Copyright: © Quan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Correlation between microRNA (miRNA)‑206 and miRNA‑145 expression and prognosis in breast cancer was investigated. Breast cancer specimens and paracancerous tissues of 372 breast cancer patients who underwent surgical resection in the First Affiliated Hospital of Shantou University Medical College from September 2010 to September 2014 were included. qRT‑PCR was used to detect the expression of miR‑206 and miR‑145 in breast cancer and paracancerous tissues, and patients were divided into high and low expression groups according to the median expression level to plot survival curve. Expression levels of miR‑145 and miR‑206 in breast cancer tissues were 2.24±1.23 and 0.76±0.24, respectively. Expression level of miR‑145 was significantly lower, while expression level of miR‑206 was significantly higher in tumor tissues than in paracancerous tissues (p<0.05). The 3‑year survival rates of miR‑145 low expression group and miR‑206 high expression group were also lower than that of miR‑145 high expression group and miR‑206 low expression group, respectively (p<0.05). Expression of miR‑206 is upregulated and expression of miR‑145 is downregulated in breast cancer, which may have an impact on the prognosis of patients. miR‑206 and miR‑145 may serve as important indicators to predict prognosis of patients with breast cancer in the future.

View Figures

View References

1	Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Etti J, Patel R, Pinter T, Schmidt M, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 16:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
2	Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel Members: Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
3	Swain SM, Baselga J, Kim SB, Ro J, Semiglazov VM, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, et al: CLEOPATRA Study Group: Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 372:724–734. 2015. View Article : Google Scholar : PubMed/NCBI
4	Turner NC, Ro J, André F, Loi S, Verma S, Iwata HN, Loibl S, Bartlett Huang C, Zhang K, et al: PALOMA3 Study Group: Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 373:209–219. 2015. View Article : Google Scholar : PubMed/NCBI
5	Hindié E and Groheux D: Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 373:1877–1878. 2015. View Article : Google Scholar : PubMed/NCBI
6	Narimatsu R and Patterson BK: High-throughput cervical cancer screening using intracellular human papillomavirus E6 and E7 mRNA quantification by flow cytometry. Am J Clin Pathol. 123:716–723. 2005. View Article : Google Scholar : PubMed/NCBI
7	Xu TP, Liu XX, Xia R, Yin L, Kong R, Chen WM, Huang MD and Shu YQ: SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer. Oncogene. 34:5648–5661. 2015. View Article : Google Scholar : PubMed/NCBI
8	Kim KT, Lee HW, Lee HO, Kim SC, Seo YJ, Chung W, Eum HH, Nam DH, Kim J, Joo KM, et al: Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. Genome Biol. 16:1272015. View Article : Google Scholar : PubMed/NCBI
9	Sun C, Liu Z, Li S, Yang C, Xue R, Xi Y, Wang L, Wang S, He Q, Huang J, et al: Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget. 6:25533–25574. 2015. View Article : Google Scholar : PubMed/NCBI
10	Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
11	Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, et al: Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 373:2005–2014. 2015. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A, Maingon P, Valli M, et al: EORTC Radiation Oncology and Breast Cancer Groups: Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 373:317–327. 2015. View Article : Google Scholar : PubMed/NCBI
14	Tutt A, Ellis P, Kilburn L, Gilett C, Pinder S, Abraham J, Barrett S, Barrett-Lee P, Chan S and Cheang M: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res. 75 9 Suppl:Abst S3-01. 2015. View Article : Google Scholar
15	Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, et al: Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 67:33–41. 2015. View Article : Google Scholar : PubMed/NCBI
16	Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, et al: Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 67:241–249. 2015. View Article : Google Scholar : PubMed/NCBI
17	Gupta Y, Möller S, Witte M, Belheouane M, Sezin T, Hirose M, Vorobyev A, Niesar F, Bischof J, Ludwig RJ, et al: Dissecting genetics of cutaneous miRNA in a mouse model of an autoimmune blistering disease. BMC Genomics. 17:1122016. View Article : Google Scholar : PubMed/NCBI
18	Ge X, Lyu P, Cao Z, Li J, Guo G, Xia W and Gu Y: Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. Biochem Biophys Res Commun. 463:1115–1121. 2015. View Article : Google Scholar : PubMed/NCBI
19	Eades G, Wolfson B, Zhang Y, Li Q, Yao Y and Zhou Q: lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6. Mol Cancer Res. 13:330–338. 2015. View Article : Google Scholar : PubMed/NCBI
20	Kim TH, Song JY, Park H, Jeong JY, Kwon AY, Heo JH, Kang H, Kim G and An HJ: miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma. Cancer Lett. 356:(2 Pt B). 1–945. 2015. View Article : Google Scholar
21	Oksuz Z, Serin MS, Kaplan E, Dogen A, Tezcan S, Aslan G, Emekdas G, Sezgin O, Altintas E and Tiftik EN: Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma. Mol Biol Rep. 42:713–720. 2015. View Article : Google Scholar : PubMed/NCBI